What the changes say
- Pricing pressure is more prominent, including Medicaid rebates, prior authorization, managed-care restrictions, and possible MFN changes.
- FILSPARI’s FSGS approval remains uncertain after DUPLEX missed its two-year eGFR endpoint and FDA review moved to April 13, 2026.
- International suppliers, data-protection rules, cyberattacks, and post-Brexit UK requirements add operational complexity.
- Chugai’s sparsentan deal creates milestone and royalty opportunities that depend on regulatory approvals and regional sales.
What changed since the prior 10-K
New
- NewRisks Related to the Commercialization of Our Products
and regulatory changes may affect our business, operations, or financial condition. If MFN pricing or other legal or regulatory changes are implemented in a way that is broadly applicable to our products, there could be a material negative impact
Medicaid rebates, prior authorization, managed-care restrictions, unemployment, and potential MFN pricing could reduce coverage, prices, and reimbursement.
- NewRisks Related to the Development of our Product Candidates
addition, such delays could allow our competitors to bring products to market before we do and impair our ability to commercialize our products or product candidates
Additional testing, failed or modest trial results, or safety concerns could delay approval; DUPLEX missed its primary FSGS eGFR endpoint.
- NewRisks Related to the Development of our Product Candidates
surrogate endpoint in kidney disease is a relatively new regulatory development, and, as the field continues to evolve, new learnings may impact regulatory viewpoints
FDA approval of FILSPARI for FSGS remains uncertain after DUPLEX missed its endpoint, with the sNDA decision extended to April 13, 2026.
- NewRisks Related to our Products and Product Candidates
patent applications will result in issued patents, issue on a timeline that provides material protection, or, if issued, contain claims of commercially meaningful scope
Patent filings, regulatory exclusivity, and patent-term extensions may fail to provide the expected duration or commercial scope of protection.
- NewRisks Related to Our Business
International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospects
Tariffs, sanctions, export controls, or trade barriers could disrupt international pharmaceutical supplies, including APIs and equipment sourced from China.
- NewRisks Related to Our Business
events under these various agreements might not be achieved, that our licensees may not achieve sales that would entitle us to royalty payments, and that any or all of the consideration tied to the achievement of the milestone events and/or royalties might not be received
After Chugai acquired Renalys, future sparsentan milestone payments and royalties from Japan, South Korea, and Taiwan depend on approvals and sales.
- NewRisks Related to Our Business
plaintiffs. Our inability or failure to obtain consent for these practices could result in adverse consequences, including class action litigation and mass arbitration demands
GDPR, UK GDPR, Brazil’s LGPD, and China’s PIPL impose complex data obligations and potentially severe fines on clinical-trial data processing.
- NewRisks Related to Our Business
In the ordinary course of our business, we and the third parties with whom we work process sensitive information
Cyberattacks, fraud, and nation-state activity could disrupt Travere’s systems, supply chain, and ability to produce, sell, and distribute products.
- NewRisks Related to Our Business
leading to a single UK decision for clinical trials, and new legal obligations mandating the registration of clinical trials in public registries and the publication of trial results within 12 months of trial conclusion
Post-Brexit UK authorization rules and clinical-trial registration and publication obligations could complicate development and marketing of products in the UK.
Dropped
- DroppedRisks Related to the Commercialization of Our Products
IgAN, it is difficult to estimate FILSPARI’s market potential or the time it will take to increase patient and physician awareness of FILSPARI and change current treatment paradigms
- DroppedRisks Related to our Products and Product Candidates
REMS in the future following sufficient experience with FILSPARI and if supported by the data, there is no guarantee that the data will support this endeavor, or even if we believe it does, that the FDA will agree with it
FILSPARI’s IgAN market adoption by patients and physicians, including awareness and treatment-paradigm changes.
- DroppedRisks Related to our Products and Product Candidates
interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property or narrow the scope of our patent protection
- DroppedRisks Related to Our Business
requiring the reporting of certain information related to drug pricing; and requiring drug manufacturers to track and report information related to payments, gifts, compensation, and other items of value to physicians and other healthcare providers
- DroppedRisks Related to Our Business
In the ordinary course of our business, we and the third parties with whom we work process proprietary, confidential, and sensitive data, including personal data (such as health-related data and data related to our clinical trials), intellectual property, and trade secrets (collectively, sensitive information)
- DroppedRisks Related to Our Business
Framework is implemented in Northern Ireland on January 1, 2025, products falling within the scope of the EU centralized procedure can only be authorized through UK national authorization procedures in Great Britain
Reworded
- 87% rewrittenRisks Related to the Development of our Product Candidates
Communications and/or feedback from regulatory authorities related to our current or planned future clinical trials does not guarantee any particular outcome from or timeline for regulatory review, and expedited regulatory review pathways may not actually lead to faster development or approval
The discussion now focuses on the DUPLEX Study and removes the prior PROTECT Study reference; regulatory feedback still does not assure approval or timing.
- 72% rewrittenRisks Related to our Products and Product Candidates
We do not currently have patent protection for certain of our commercial products. If we are unable to obtain and maintain protection for the intellectual property relating to our technology and products, their value will be adversely affected
The risk now specifically notes generic manufacturers’ skinny-label approvals for tiopronin EC, replacing the prior pending-patent discussion.
- 70% rewrittenRisks Related to Our Business
Our business could be negatively impacted by environmental, social and corporate governance (ESG) matters or our reporting of such matters
The SEC climate-disclosure example was replaced with California and EU ESG requirements that may be nonuniform and increase compliance complexity.
- 67% rewrittenRisks Related to our Products and Product Candidates
Any therapies we develop may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, thereby harming our business
The risk now adds executive, judicial, Congressional, and political challenges and amendments to the PPACA.
- 61% rewrittenRisks Related to the Commercialization of Our Products
Healthcare reform initiatives, unfavorable pricing regulations and changes in reimbursement practices of third-party payers or patients' access to insurance coverage could affect the pricing of and demand for our products
No substantive change is apparent; it continues to cover healthcare-cost controls, reimbursement changes, and payer pressure on sparsentan and pegtibatinase.
- 53% rewrittenRisks Related to Our Business
If we are not able to obtain and maintain required regulatory approvals, we will not be able to commercialize our products, and our ability to generate revenue will be materially impaired
No substantive change is apparent; it continues to emphasize extensive FDA and foreign regulation and limited regulatory experience.
- 53% rewrittenRisks Related to the Commercialization of Our Products
Our future prospects are highly dependent upon our ability to successfully develop and execute commercialization strategies for our products, including FILSPARI, and to attain market acceptance among physicians, patients and healthcare payers
The description now clarifies that FILSPARI received accelerated approval for IgAN in February 2023, rather than stating only February 2023 approval.
- 52% rewrittenRisks Related to our Products and Product Candidates
If we are unable to obtain and maintain coverage and adequate reimbursement from governments or third-party payers for any products that we may develop or if we are unable to obtain acceptable prices for those products, our prospects for generating revenue and achieving profitability will suffer
No substantive change is apparent; it continues to focus on government and commercial coverage, reimbursement, and payer evidence requirements.
- 52% rewrittenRisks Related to our Products and Product Candidates
Materials necessary to manufacture our products and product candidates may not be available on commercially reasonable terms, or at all, which may delay the development and commercialization of our products and product candidates
- 46% rewrittenRisks Related to our Products and Product Candidates
Our products may not achieve or maintain expected levels of market acceptance or commercial success
- 46% rewrittenRisks Related to Our Business
Uncertainties in the interpretation and application of existing, new and proposed tax laws and regulations could materially affect our tax obligations and effective tax rate
- 45% rewrittenRisks Related to the Development of our Product Candidates
Before obtaining regulatory approval for the sale of any of our current or future product candidates, we must subject these product candidates to extensive nonclinical and clinical testing to demonstrate their safety and efficacy for humans. Clinical trials are expensive, time-consuming and may take years to complete
- 41% rewrittenRisks Related to Our Business
We may not receive some or all of the potential milestone and/or royalty payments from our corporate and licensing transactions
- 37% rewrittenRisks Related to the Commercialization of Our Products
The commercial success of our products depends on them being considered to be effective drugs with advantages over other therapies
- 33% rewrittenRisks Related to our Indebtedness and Financial Condition
Conversion of the Notes may dilute the ownership interest of existing stockholders, including holders who had previously converted their 2029 Notes
Was: Conversion of the Notes may dilute the ownership interest of existing stockholders, including holders who had previously converted their 2025 Notes or 2029 Notes
- 30% rewrittenRisks Related to our Indebtedness and Financial Condition
We may be unable to raise the funds necessary to repurchase the 2029 Notes for cash following a fundamental change, or to pay any cash amounts due upon conversion, and our future indebtedness may limit our ability to repurchase the 2029 Notes or pay cash upon their conversion
Was: We may be unable to raise the funds necessary to repurchase the 2025 Notes and 2029 Notes for cash following a fundamental change, or to pay any cash amounts due upon conversion, and our future indebtedness may limit our ability to repurchase the 2025 Notes and 2029 Notes or pay cash upon their conversion
- 29% rewrittenRisks Related to our Indebtedness and Financial Condition
Provisions of the 2029 Notes could discourage an acquisition of us by a third party
Was: Provisions of the 2025 Notes and 2029 Notes could discourage an acquisition of us by a third party
- 25% rewrittenRisks Related to Our Business
Risks related to the use of artificial intelligence technologies could adversely affect our business, financial condition and/or operating results
- 23% rewrittenRisks Related to our Indebtedness and Financial Condition
A default under the 2029 Notes may have a material adverse effect on our financial condition
Was: A default under the 2025 Notes or 2029 Notes may have a material adverse effect on our financial condition
All 62 risk factors
Headings as the filing states them, in filing order.
Risks Related to the Commercialization of Our Products
- 01Our future prospects are highly dependent upon our ability to successfully develop and execute commercialization strategies for our products, including FILSPARI, and to attain market acceptance among physicians, patients and healthcare payers53% rewritten
- 02In order to operate our business and increase adoption and sales of our products, we need to continue to develop our commercial organization, including maintaining a highly experienced and skilled workforce with qualified sales representatives
- 03The commercial success of our products depends on them being considered to be effective drugs with advantages over other therapies37% rewritten
- 04We face substantial generic and other competition, and our operating results will suffer if we fail to compete effectively
- 05Healthcare reform initiatives, unfavorable pricing regulations and changes in reimbursement practices of third-party payers or patients' access to insurance coverage could affect the pricing of and demand for our products61% rewritten
- 06and regulatory changes may affect our business, operations, or financial condition. If MFN pricing or other legal or regulatory changes are implemented in a way that is broadly applicable to our products, there could be a material negative impactNew
- 07We are dependent on third parties to manufacture and distribute our products
- 08Governments outside the United States tend to impose strict price controls and reimbursement approval policies, which may adversely affect our prospects for generating revenue
- 09We may not be able to rely on orphan drug exclusivity for our products
- 10Guidelines and recommendations published by various organizations may impact the use of our products
Risks Related to the Development of our Product Candidates
- 11Our clinical trials are expensive and time-consuming and may fail to demonstrate the safety and efficacy of our product candidates
- 12Before obtaining regulatory approval for the sale of any of our current or future product candidates, we must subject these product candidates to extensive nonclinical and clinical testing to demonstrate their safety and efficacy for humans. Clinical trials are expensive, time-consuming and may take years to complete45% rewritten
- 13addition, such delays could allow our competitors to bring products to market before we do and impair our ability to commercialize our products or product candidatesNew
- 14Success in nonclinical testing and early clinical trials does not ensure that later clinical trials will be successful
- 15Communications and/or feedback from regulatory authorities related to our current or planned future clinical trials does not guarantee any particular outcome from or timeline for regulatory review, and expedited regulatory review pathways may not actually lead to faster development or approval87% rewritten
- 16surrogate endpoint in kidney disease is a relatively new regulatory development, and, as the field continues to evolve, new learnings may impact regulatory viewpointsNew
- 17Interim, topline and preliminary data from our clinical trials that we announce or publish may change materially as more patient data become available and audit and verification procedures are complete
- 18We and/or a collaborative partner are or will be subject to ongoing regulatory obligations and continued regulatory review for our approved products and any product candidates that receive regulatory approval
- 19The third-party clinical investigators and contract research organizations that we rely upon to conduct our clinical trials may not be diligent, careful or timely, and may make mistakes, in the conduct of our trials
Risks Related to our Products and Product Candidates
- 20Our products may not achieve or maintain expected levels of market acceptance or commercial success46% rewritten
- 21The market opportunities for our products and product candidates may be smaller than we believe they are
- 22Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval or commercialization
- 23We do not currently have patent protection for certain of our commercial products. If we are unable to obtain and maintain protection for the intellectual property relating to our technology and products, their value will be adversely affected72% rewritten
- 24patent applications will result in issued patents, issue on a timeline that provides material protection, or, if issued, contain claims of commercially meaningful scopeNew
- 25We expect to rely on orphan drug status to develop and commercialize certain of our products and product candidates, but our orphan drug designations may not confer marketing exclusivity or other expected commercial benefits
- 26Any therapies we develop may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, thereby harming our business67% rewritten
- 27If we are unable to obtain and maintain coverage and adequate reimbursement from governments or third-party payers for any products that we may develop or if we are unable to obtain acceptable prices for those products, our prospects for generating revenue and achieving profitability will suffer52% rewritten
- 28We face potential product liability exposure far in excess of our limited insurance coverage
- 29We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do. Our operating results will suffer if we fail to compete effectively
- 30Materials necessary to manufacture our products and product candidates may not be available on commercially reasonable terms, or at all, which may delay the development and commercialization of our products and product candidates52% rewritten
Risks Related to Our Business
- 31International trade policies, including tariffs, sanctions and trade barriers may adversely affect our business, financial condition, results of operations and prospectsNew
- 32Our limited operating history makes it difficult to evaluate our future prospects, and our profitability in the future is uncertain
- 33We depend on a highly experienced and skilled workforce to grow and operate our business. If we are unable to attract, retain and engage our employees, we may not be able to grow effectively
- 34Health epidemics or pandemics could materially adversely affect our business, results of operations and financial condition
- 35We will likely experience fluctuations in operating results and could incur substantial losses
- 36Negative publicity regarding any of our products could impair our ability to market any such product and may require us to spend time and money to address these issues
- 37We may not have sufficient insurance to cover our liability in any current or future litigation claims either due to coverage limits or as a result of insurance carriers seeking to deny coverage of such claims
- 38We may need substantial funding and may be unable to raise capital when needed
- 39The market price for shares of our common stock may be volatile and purchasers of our common stock could incur substantial losses
- 40We may not receive some or all of the potential milestone and/or royalty payments from our corporate and licensing transactions41% rewritten
- 41events under these various agreements might not be achieved, that our licensees may not achieve sales that would entitle us to royalty payments, and that any or all of the consideration tied to the achievement of the milestone events and/or royalties might not be receivedNew
- 42We may be unable to successfully integrate new products or businesses we may acquire
- 43Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop
- 44We may become involved in litigation matters, which could result in substantial costs, divert management's attention and otherwise have a material adverse effect on our business, operating results or financial condition
- 45We are subject to significant ongoing regulatory obligations and oversight, which may result in significant additional expense and may limit our commercial success
- 46If we are not able to obtain and maintain required regulatory approvals, we will not be able to commercialize our products, and our ability to generate revenue will be materially impaired53% rewritten
- 47plaintiffs. Our inability or failure to obtain consent for these practices could result in adverse consequences, including class action litigation and mass arbitration demandsNew
- 48In the ordinary course of our business, we and the third parties with whom we work process sensitive informationNew
- 49Risks related to the use of artificial intelligence technologies could adversely affect our business, financial condition and/or operating results25% rewritten
- 50Uncertainties in the interpretation and application of existing, new and proposed tax laws and regulations could materially affect our tax obligations and effective tax rate46% rewritten
- 51Our ability to use net operating loss carryforwards and certain other tax attributes to offset future taxable income and taxes may be subject to limitations
- 52Our business could be negatively impacted by environmental, social and corporate governance (ESG) matters or our reporting of such matters70% rewritten
- 53leading to a single UK decision for clinical trials, and new legal obligations mandating the registration of clinical trials in public registries and the publication of trial results within 12 months of trial conclusionNew
- 54Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses
- 55Adverse developments affecting the financial services industry could adversely affect our current and projected business operations and our financial condition and results of operations
- 56We maintain our cash at financial institutions, often in balances that exceed federally insured limits
Risks Related to our Indebtedness and Financial Condition
- 57Our indebtedness could adversely affect our financial condition
- 58We may be unable to raise the funds necessary to repurchase the 2029 Notes for cash following a fundamental change, or to pay any cash amounts due upon conversion, and our future indebtedness may limit our ability to repurchase the 2029 Notes or pay cash upon their conversion30% rewritten
- 59A default under the 2029 Notes may have a material adverse effect on our financial condition23% rewritten
- 60Provisions of the 2029 Notes could discourage an acquisition of us by a third party29% rewritten
- 61Conversion of the Notes may dilute the ownership interest of existing stockholders, including holders who had previously converted their 2029 Notes33% rewritten
- 62Unstable market, economic and geopolitical conditions may have serious adverse consequences on our business, financial condition and stock price
Other Travere Therapeutics 10-Ks
- FY2024 10-K risk factors59 risks
Commercial success depends entirely on sales adoption of FILSPARI for primary IgAN and Thiola.
Filed Feb 21, 2025
About this page
The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.